Vaxart

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual Meeting indicate that all four…

<!-- Name:DistributionId Value:8790320 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8748472 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical…

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where…

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast…

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical…